

**COMMONWEALTH OF KENTUCKY  
CABINET FOR HEALTH AND FAMILY SERVICES  
DEPARTMENT FOR MEDICAID SERVICES  
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

**Capitol Annex -Room 149**

700 Capital Avenue Frankfort, Kentucky 40601

Thursday, November 15, 2018

1:00 P.M. to 4:00 P.M.

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session**
- III. Old Business**
  - a. Approval of Meeting Minutes
  - b. Lucemyra New Product Review
- IV. New Business**
  - a. New Products to Market
    - i. Tibsovo<sup>®</sup> (Oncology, Oral – Hematologic)
    - ii. Braftovi<sup>™</sup> (Oncology, Oral – Skin)
    - iii. Mektovi<sup>®</sup> (Oncology, Oral – Skin)
    - iv. Doptelet<sup>®</sup> (Thrombopoiesis Stimulating Agents)
    - v. Mulpleta<sup>®</sup> (Thrombopoiesis Stimulating Agents)
  - b. New Product(s) to Market to be reviewed along with their respective classes
    - i. Ilumya<sup>™</sup> (Cytokine and CAM Antagonists)
- V. Clinical Criteria Review**
  - a. Austedo (Movement Disorders)
  - b. Ingrezza (Movement Disorders)
- VI. Therapeutic Classes with Recommended Changes**
  - a. Acne Agents, Topical
  - b. Anticholinergics/Antispasmodics
  - c. Antiemetics & Antivertigo Agents
    - i. Anti-Emetics: Other
    - ii. Oral Anti-Emetics: 5-HT<sub>3</sub> Antagonists
    - iii. Oral Anti-Emetics: Delta-9-THC Derivatives
    - iv. Oral Anti-Emetics: NK-1 Antagonists
  - d. Antifungals, Topical
  - e. Antiparasitics, Topical
  - f. Bile Salts
  - g. Cytokine and CAM Antagonists (includes new agent Ilumya<sup>™</sup>)
  - h. Multiple Sclerosis Agents
  - i. Ophthalmics for Allergic Conjunctivitis
  - j. Ophthalmic Antibiotics
    - i. Ophthalmic Antibiotics, Non-Quinolones

- ii. Ophthalmic Antifungals
- iii. Ophthalmic Macrolides
- iv. Ophthalmic Quinolones
- k. Otic Antibiotics
- l. Steroids, Topical (Low Potency)

**VII. Consent Agenda**

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

Acne Agents, Oral	Ophthalmic Immunomodulators
Anti-Ulcer Protectants	Ophthalmics, Antibiotic-Steroid Combinations
Antibiotics, Topical	Ophthalmics, Anti-inflammatories
Antidiarrheals	Ophthalmics, Antivirals
Antipsoriatics, Oral	Ophthalmics, Glaucoma Agents
Antipsoriatics, Topical	Ophthalmics, Mydriatic
Antivirals, Topical	Ophthalmics, Vasoconstrictors
GI Motility, Chronic	Otic Anti-Infectives and Anesthetics
H. Pylori Treatment	Otics, Anti-Inflammatory
Histamine II Receptor Blockers	Proton Pump Inhibitors
Immunomodulators, Atopic Dermatitis	Rosacea Agents, Topical
Immunosuppressives, Oral	Steroids, Topical (Medium, High, Very High)
Laxatives and Cathartics	Ulcerative Colitis Agents

**VIII. Adjournment**

- a. Schedule of Upcoming Meetings
  - i. **January 17, 2019**
  - ii. **March 21, 2019**
  - iii. **May 16, 2019**
  - iv. **July 18, 2019**
  - v. **September 19, 2019**
  - vi. **November 21, 2019**
- b. Collection of Travel Vouchers

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.